Prohost Biotech - Exclusive Biotech Research - A Comprehensive Resource for Biotech News

A Quick Opinion on the CRISPR Patenting Story. Gillead’s Improvement of HIV Treatment

February 17, 2017 0

About the CRISPR/Cas9 Gene Editing Patent Shareholders of biotechnology firms specialized in CRISPR gene editing technology …

Seattle Genetics’ Agreement with Immunomedics: The Benefit Vs. the Risk

February 14, 2017 0

Immunomedics (IMMU) and Seattle Genetics (SGEN) announced an exclusive global licensing agreement enabling Seattle Genetics to …

Why Agenus and Incyte Are Both Winners Amending Their Original Agreement

February 14, 2017 0

Incyte (INCY) and Agenus (AGEN) announced an amendment of the License, Development and Commercialization Agreement that …

Interpreting Portola Pharmaceuticals’ News

February 9, 2017 0

The FDA’s Center for Drug Evaluation and Research (CDER) informed Portola (PTLA) that it does not …

Gilead Sciences: A Case Study

February 9, 2017 0

Gilead Sciences (GILD) was subjected to what we believe is an exaggerated stock selloff following the …

Prohost Letter #404 Part 2

February 6, 2017 0

Prohost Letter #404 Part 2 Synthetic Biology (2) A Brief History DNA is the software of …

How Good Is Xoma’s Good News?

February 4, 2017 0

XOMA Establishes Proof-of-Concept for 358 in Congenital Hyperinsulinism and Hypoglycemia Post-Bariatric Surgery Congenital Hyperinsulinism Phase 2 …

Companies Targeted for Takeover Yet Can Thrive on their Own

February 2, 2017 0

It seems that the global Takeda (TKPYY) has guessed well what it should pick in order …

Incyte and Calithera Collaboration Is Fair and Lucrative for Both Firms

January 30, 2017 0

Incyte and Calithera Biosciences Announce Global Collaboration to Develop and Commercialize CB-1158, a Small Molecule Arginase Inhibitor …

Prohost Letter #404 Part 1

January 23, 2017 0

Prohost Letter #404 Part 1 HAPPY SPIRITUAL HOLIDAYS HAPPY NEW YEA

Welcoming Jounce Therapeutics (JNCE) as a Public Company

January 22, 2017 0

Today, Jounce Therapeutics has begun trading on the NASDAQ under the ticker symbol (JNCE). The Company, …

While You Were Sleeping

January 17, 2017 0

A few months ago, we heard news that a Belgium firm called Celyad (CYAD) has concluded …

Vertex and Merck KGaA Agreement Suits Both Firms

January 13, 2017 0

Vertex (VRTX) entered into a licensing agreement with Merck KGaA, Darmstadt, Germany for the worldwide development …

Will the FDA Approve Amgen’s Drug Parsabiv Next Month?

January 11, 2017 0

Amgen (AMGN) The Journal of the American Medical Association (JAMA) published findings from three Phase 3 …

Takeda Acquires Ariad for $5.2 Billion

January 9, 2017 0

ARIAD Pharmaceuticals’ (ARIA) stock jumped 75% today. The oncology firm entered into a definitive agreement to be …

Halozyme’s PEGPH20 Trial Results Are Worth Appreciating Not Doubting

January 6, 2017 0

Extremely important, not just exciting, were the results of Halozyme Therapeutics’s (HALO) Phase 2 randomized, multi-center …

Some More Important News that Precedes the Upcoming Prohost Letter

January 5, 2017 0

GILEAD (GILD) One analyst who aimed at bringing only the negatives about biotech has finally succeeded …

A Few News Before Posting the New Year Prohost Letter

January 3, 2017 0

Hi and Happy New Year 2017 In a couple of days, you will receive the NEW …

The FDA Manufacturing Issues. Why Portola Rallied but is Still Way Undervalued

December 26, 2016 0

MANUFACTURING ISSUES?! Why PORTOLA Stock Rallied? On Aug. 17, 2016, we learned that the FDA sent …

Misunderstanding the Bipartisan Senate Report on Drug Prices. See Also: Incyte Signs a Promising Collaborative Agreement with Merus N.V.

December 22, 2016 0

Observing the biotech sector’s stock prices post losses yesterday, Wednesday, Dec. 21 convinced us that investors …

Exclusive Market Insight

& Scientific analysis

Latest Articlesddd

A Quick Opinion on the CRISPR Patenting Story. Gillead’s Improvement of HIV Treatment

Seattle Genetics’ Agreement with Immunomedics: The Benefit Vs. the Risk

Why Agenus and Incyte Are Both Winners Amending Their Original Agreement

Interpreting Portola Pharmaceuticals’ News

Gilead Sciences: A Case Study

Prohost Letter #404 Part 2

How Good Is Xoma’s Good News?

Companies Targeted for Takeover Yet Can Thrive on their Own

Incyte and Calithera Collaboration Is Fair and Lucrative for Both Firms

Prohost Letter #404 Part 1

Welcoming Jounce Therapeutics (JNCE) as a Public Company

While You Were Sleeping

Vertex and Merck KGaA Agreement Suits Both Firms

Will the FDA Approve Amgen’s Drug Parsabiv Next Month?

Takeda Acquires Ariad for $5.2 Billion

Halozyme’s PEGPH20 Trial Results Are Worth Appreciating Not Doubting

Some More Important News that Precedes the Upcoming Prohost Letter

A Few News Before Posting the New Year Prohost Letter

The FDA Manufacturing Issues. Why Portola Rallied but is Still Way Undervalued

Misunderstanding the Bipartisan Senate Report on Drug Prices. See Also: Incyte Signs a Promising Collaborative Agreement with Merus N.V.